Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP & Chief Medical Officer

President and CEO

EVP & Chief Commercial Officer

EVP, Chief Development Officer

SVP, General Counsel&Secretary

EVP, CFO & Treasurer

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nu...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-22	Premium	sold	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-04-04	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-05	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-01	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP & Chief Commercial Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP, Chief Development Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	SVP, General Counsel&Secretary
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP, CFO & Treasurer
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-02-29	Premium	sold	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-02-29	Premium	sold	Premium	Premium	Premium	President and CEO
2024-02-29	Premium	sold	Premium	Premium	Premium	EVP, Chief Development Officer
2024-02-29	Premium	sold	Premium	Premium	Premium	EVP & Chief Commercial Officer
2024-02-29	Premium	sold	Premium	Premium	Premium	SVP, General Counsel&Secretary
2024-02-29	Premium	sold	Premium	Premium	Premium	EVP, CFO & Treasurer
2024-02-28	Premium	acquired	Premium	Premium	Premium	EVP, Chief Development Officer
2024-02-28	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-28	Premium	acquired	Premium	Premium	Premium	EVP, CFO & Treasurer
2024-02-28	Premium	acquired	Premium	Premium	Premium	SVP, General Counsel&Secretary
2024-02-28	Premium	acquired	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-02-28	Premium	acquired	Premium	Premium	Premium	EVP & Chief Commercial Officer
2024-02-27	Premium	sold	Premium	Premium	Premium	EVP, CFO & Treasurer
2024-02-15	Premium	sold	Premium	Premium	Premium	EVP, Chief Development Officer
2024-02-06	Premium	sold	Premium	Premium	Premium	President and CEO
2024-02-06	Premium	sold	Premium	Premium	Premium	EVP, CFO & Treasurer

KPTI - Karyopharm Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for KPTI